Loading
Armata Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Innoviva, Inc., was filed 01 Apr 2022.
Armata Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Armata Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 3 filings came from 2 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
With 3 filings in twelve months, the company is quieter than the median of 19 filings across the 5,814 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 3 purchases and no sales.
No insider has bought Armata Pharmaceuticals, Inc. shares on the open market in the past twelve months. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
12
Thresholds
n/a
Buy Volume
€44M
3 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -68.5%Entry US$5.40 · Close at T+365 US$1.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Armata Pharmaceuticals, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$17.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.78
Analyst consensus
2 analystsStrong buy
US$15.00Target US$17.50(+529%)US$20.00
Income statement
EBITDA-US$155.7M
Net income-US$173.8M0.0% margin
Valuation
Beta1.41
Balance sheet & cash
Market capUS$103.4M
Total debtUS$288M
Free Cash Flow-US$26.3M
Profitability & ownership
ROA-25.8%
% insiders67.6%
% institutions13.5%
Last declaration on 14 July 2026
Declarations12 total
14,041 shares@ US$4.260.044% mcap29.0% of flowCommon StockSEC:0001104659-26-083516:0
1,030 shares@ US$10.5483.6% of flowCommon StockSEC:0001104659-26-029712:0
4,919 shares@ US$10.5424.9% of flowCommon StockSEC:0001104659-26-029711:0
13,637 shares@ US$2.2714.7% of flowCommon StockSEC:0001104659-25-067746:0
1,027 shares@ US$1.9516.4% of flowCommon StockSEC:0001104659-25-039414:0
22,925 shares@ US$2.6831.4% of flowCommon StockSEC:0001104659-25-039417:0
10,000 shares0Common StockSEC:0001104659-24-035728:0
60,000 shares0Common StockSEC:0001104659-24-035723:0
200,000 shares0Common StockSEC:0001104659-23-129365:0
5,385,208 shares@ US$5.0055.8% of flowCommon StockSEC:0001567619-22-007861:0
Canonical exit: 29 Jun 2022 (T+90)
3,614,792 shares@ US$5.0036.3% of flowCommon StockSEC:0001567619-22-003750:0
Canonical exit: 10 May 2022 (T+90)
1,212,122 shares@ US$3.307.9% of flowCommon StockSEC:0001567619-21-019063:0
Canonical exit: 27 Jan 2022 (T+90)
12 of 12 declarations
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. (ticker: ARMP) is a U.S.-listed biotechnology company trading on NYSE American, placing it within the broader NYSE/NASDAQ universe of growth-oriented healthcare names. Headquartered in Los Angeles, California, in the United States, Armata develops bacteriophage-based therapeutics: naturally occurring or engineered viruses designed to selectively attack specific bacterial pathogens. The company occupies a specialized niche focused on antibiotic-resistant and difficult-to-treat infections, a therapeutic area with meaningful unmet medical need and, potentially, significant long-term value creation if clinical and regulatory milestones are achieved.
Armata’s origins are rooted in phage therapy science and the development of proprietary know-how around identifying, characterizing, and engineering bacteriophages. Over time, the company has built an integrated platform that also includes phage-specific, host-engineered cGMP manufacturing capabilities. That vertical integration is strategically important: it supports tighter control over product quality, scalability, and eventual commercialization readiness. Armata is best described as a late clinical-stage biotech company rather than a commercial pharmaceutical business, meaning it remains dependent on external capital and has not yet established a stable revenue base from product sales.
Read moreShow less
Its core pipeline targets high-priority bacterial pathogens, with lead programs including candidates for Pseudomonas aeruginosa and Staphylococcus aureus. These pathogens are especially relevant in hospital and intensive-care settings, where drug resistance can make infections hard to eradicate and costly to treat. Armata’s approach combines natural and synthetic phage candidates, including multi-phage constructs, aiming to deliver pathogen-specific activity while addressing resistance limitations that often reduce the effectiveness of conventional antibiotics. In competitive terms, Armata operates in a small but scientifically compelling segment of biotech, alongside a limited number of companies exploring phage therapy and adjacent anti-infective technologies.
Recent company developments underscore both progress and financial risk. In early 2026, Armata amended multiple credit arrangements with Innoviva Strategic Opportunities LLC, extending maturity dates to June 1, 2027. The company also disclosed going-concern language in its 2026 filings, reflecting recurring losses, negative operating cash flow, and a continuing need for additional funding. At the same time, Armata announced regulatory momentum for AP-SA02, its Staphylococcus aureus multi-phage candidate, including FDA Qualified Infectious Disease Product status for intravenous adjunct treatment of complicated S. aureus bacteremia. For investors, Armata is a high-risk, high-science biotech story: promising platform potential, but with substantial financing, execution, and clinical-development risk ahead.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
